Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks

Stock News09-21 15:17

Citi has issued a research report following the joint release of the 15th Five-Year Plan for the Pharmaceutical Industry Development by the Ministry of Industry and Information Technology and other departments. The plan focuses on shifting China's pharmaceutical industry from scale-driven growth to innovation-led, quality-oriented development, with a clear objective of achieving world-leading status by 2030. The coverage spans innovative drugs, advanced medical devices, AI-powered drug discovery, and CDMO/CRO services, reflecting broad policy support across the entire value chain.

The bank believes this policy direction benefits domestic innovative drug developers and biotech firms, AI-driven drug discovery companies, CRO/CDMO service providers, high-end medical device manufacturers, in-vitro diagnostics (IVD) equipment producers, and innovative traditional Chinese medicine enterprises. Citi's top picks in this space include CSPC PHARMA (01093), HENGRUI PHARMA (01276), INNOVENT BIO (01801), SKB BIO (06990), WUXI BIO (02269), TIGERMED (03347), and 英硅智能 (03696).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment